Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
Sanofi's Sarclisa becomes the first cancer drug to receive FDA approval for delivery via a wearable on-body injector for multiple myeloma patients.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
The FDA approved Sanofi's subcutaneous isatuximab, known as Sarclisa Escena, for the treatment of multiple myeloma. This marked the first cancer drug delivered via an on-body injector.
Epilogue added 106d ago, after coverage quieted.
The brief
The United States Food and Drug Administration has granted approval for Sanofi's Sarclisa Escena, an isatuximab-irfc formulation designed for subcutaneous injection. This regulatory milestone, which took place on July 9, marks the first time a cancer drug has been approved for delivery through an on-body injector. The drug is specifically indicated for the treatment of patients with multiple myeloma, a type of blood cancer. By utilizing a wearable injector, the delivery method for this isatuximab-based therapy shifts from traditional administration to a more portable, on-body system. Major industry outlets including Reuters and Fierce Pharma highlight the novelty of the wearable injector technology in the oncology space.
According to reporting from AJMC, the approval is expected to increase competition within the anti-CD38 therapy market for myeloma. Pharmaceutical Executive and Oncodaily have detailed the specific approval of the subcutaneous version of the drug, while PharmTech.com has focused on the broader implications that this approval has for the treatment landscape of multiple myeloma. The consensus across these sources is that the on-body delivery system represents a significant shift in how these types of cancer medications are administered. Contextually, the approval of isatuximab-irfc occurs as Sanofi navigates other regulatory and legal challenges. Yahoo Finance reports that while the company has won this FDA nod for Sarclisa Escena, it is simultaneously facing a situation where the European Union has opened an antitrust probe into the company.
This intersection of a major product win in the United States and an ongoing legal investigation in Europe creates a complex business environment for Sanofi as it seeks to expand its oncology portfolio and maintain its market position against other anti-CD38 competitors. Future developments to monitor include the market reception of the on-body injector and how this delivery method affects the competitive dynamics of the myeloma treatment market. As noted by AJMC, the increased competition in the anti-CD38 sector will be a key point of interest. Furthermore, the outcome of the EU antitrust probe mentioned by Yahoo Finance will remain a critical factor in Sanofi's global operational outlook. Coverage does not yet specify the exact rollout date or the pricing for the new subcutaneous formulation in the US market.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 115d ago.
Quick answers
What is the significance of Sarclisa's recent FDA approval?
It is the first cancer drug to be approved for delivery via an on-body injector.
What condition is Sarclisa Escena used to treat?
It is used for the treatment of multiple myeloma, a form of blood cancer.
What other news is affecting Sanofi alongside this approval?
Yahoo Finance reports that the European Union has opened an antitrust probe into the company.
Coverage (9)
- Galina Bernstein: FDA Approves Subcutaneous Isatuximab for Multiple Myeloma Oncodaily · 130d ago
- FDA Approves Subcutaneous Isatuximab for Multiple Myeloma Oncodaily · 130d ago
- FDA Approves Subcutaneous Sarclisa Escena Pharmaceutical Executive · 130d ago
- FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma AJMC · 130d ago
- Sanofi (ENXTPA:SAN) Wins FDA Nod For Sarclisa Escena As EU Opens Antitrust Probe Yahoo Finance · 130d ago
- FDA Approves Isatuximab-Irfc For Subcutaneous Injection For Multiple Myeloma Indications On July 9 TradingView · 130d ago
- The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma PharmTech.com · 130d ago
- US FDA approves Sanofi's wearable injector form of blood cancer drug Reuters · 130d ago
- Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector Fierce Pharma · 130d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Seawolf Therapeutics launches with $100 million from Versant Ventures and Eli Lilly to develop non-viral gene therapies targeting obesity, muscle loss, and osteoporosis.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.